how to use data rescue 4 for time capsule

AURTIs are predominantly viral, and most AURTIs are mild and self-limited within 7 days 4. According to the International Statistical Classification of Diseases (ICD-10), AURTIs include common cold, acute sinusitis, acute pharyngitis, acute tonsillitis, acute laryngitis and tracheitis, acute epiglottitis, and acute upper respiratory infections of multiple and unspecified sites 3. Acute upper respiratory tract infections (AURTIs) are the most common type of URTIs. The global 6090,503 disability-adjusted life years due to URTIs were lost in 2016 2. In 2017, the global incidence of URTIs was 17.1 billion worldwide 1, which posed substantial socioeconomic burden to public health. Upper respiratory tract infections (URTIs) are one of the most commonly occurring diseases. However, high quality placebo controlled trials are warranted to confirm its benefit. No serious adverse events were reported.Ĭonclusion: Low certainty evidence suggests that SFJD appears to shorten the duration of symptoms in AURTIs, improve cure rate and seems safe for application. SFJD also improving their cure rate with a range (1–5 days). SFJD in combination with conventional drug was associated with in common cold shortening the duration of fever (MD −1.54 days, 95% CI, I 2 = 80%, n = 385, 3 trials) and cough (MD −1.22 days, 95% CI ) in herpangina, shortening the duration of fever (MD -0.68 days, 95% CI, I 2 = 68%, n = 140, 2 trials) and blistering (MD −0.99 days, 95% CI, n = 386, 3 trials) in acute tonsillitis and acute pharyngitis shortening the duration of fever (MD −1.13 days, 95% CI, I 2 = 33%, n = 688, 7 trials) and sore throat (MD −1.13 days, 95% CI, I 2 = 84.1%, n = 1194, 10 trials). Results: Twenty-five RCTs involving 3410 patients were included. The primary outcome was resolution time of typical symptoms. Data was synthesized using risk ration (RR) or mean difference (MD) with their 95% confidence interval (CI).

Eight databases were searched from their inceptions to February 2021. Methods: Randomized controlled trials comparing SFJD with conventional drug for patients with AURTIs were included.

The aim of this study was to evaluate its effectiveness and safety for AURTIs. Background: Shufeng Jiedu capsule has been widely used in China for acute upper respiratory tract infections (AURTIs).

How to use data rescue 4 for time capsule